 AstraZeneca Plc NASDAQ: AZN and Daiichi Sankyo OTC: DSNKY announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu fam-trastuzumab deruxtecan-nxki. The trial included HER2-positive metastatic andor unresectable gastric or gastroesophageal junction GEJ adenocarcinoma patients previously treated with a trastuzumab-containing regimen. 